![]() |
市場調查報告書
商品編碼
1394980
鹽酸去氧腎上腺素市場 -按應用(鼻充血、感冒、低血壓、過敏反應、眼部疾病)、模式(內部、合約)、用途(人類、獸醫)全球預測,2023 - 2032Phenylephrine Hydrochloride Market - By Application (Nasal Decongestion, Cold, Hypotension, Allergic Reaction, Eye Diseases), Mode (In-house, Contract), Use (Human, Veterinary) Global Forecast, 2023 - 2032 |
在全球過敏和環境敏感性數量激增的推動下,鹽酸去氧腎上腺素市場規模預計在 2023 年至 2032 年期間以 7.7% 的CAGR擴大。隨著越來越多的人對環境因素產生過敏反應,對含有鹽酸去氧腎上腺素的有效減充血藥物的需求正在上升。鹽酸去氧腎上腺素能夠緩解與過敏反應相關的鼻塞,因此在過敏緩解製劑的生產中得到越來越多的採用。
此外,正在進行的旨在改進含有鹽酸去氧腎上腺素的藥物的配方和給藥方法的研發工作預計將推動市場成長。舉個例子,2023 年5 月,Eyenovia, Inc. 的Mydcombi 獲得美國FDA 批准,這是一種1%/2.5% 托吡卡胺和鹽酸去氧腎上腺素眼部噴霧劑,用於瞳孔散大的診斷程序和需要短期瞳孔的擴張。
鹽酸去氧腎上腺素產業按應用、模式、用途和地區細分。
根據模式,預計 2023 年至 2032 年合約製造領域的市佔率CAGR將達到 7.9%。合約製造為製藥公司提供了簡化生產和最佳化成本的策略方法。此外,將製造流程外包給專業合約製造商可確保高效生產、品質合規性和可擴展性。這種模式還允許製藥公司專注於研發活動,同時利用合約製造商的專業知識,及時、經濟高效地生產基於鹽酸去氧腎上腺素的藥物。
在應用方面,來自過敏反應領域的鹽酸去氧腎上腺素產業在2022年產生了可觀的收入,並有望在2023年至2032年期間實現7%的成長率。這可歸因於用於緩解與過敏反應相關的鼻塞的藥物的使用增加。過敏、環境因素和生活方式改變的盛行率不斷上升,也增加了對含有鹽酸去氧腎上腺素的藥品的需求,從而推動了該領域的成長。
從地區來看,在製藥和醫療保健產業不斷擴大的推動下,亞太地區鹽酸去氧腎上腺素市場預計 2023 年至 2032 年CAGR為 8.1%。呼吸系統疾病盛行率的上升和對減充血藥物的持續需求導致對鹽酸去氧腎上腺素的需求增加。此外,亞太地區主要國家人口的成長、都市化和生活方式的變化正在推動人們對非處方藥的偏好,進一步提振該地區的產業前景。
Phenylephrine Hydrochloride Market size is poised to expand at 7.7% CAGR from 2023-2032, driven by the surge in the number of allergies and environmental sensitivities worldwide. With more individuals experiencing allergic reactions to environmental factors, the demand for effective decongestant medications containing phenylephrine hydrochloride is rising. The ability to alleviate nasal congestion associated with allergic response is contributing to the increasing adoption of phenylephrine hydrochloride in the production of allergy relief formulations.
Furthermore, the ongoing R&D efforts aimed at improving formulations and delivery methods for medications containing phenylephrine hydrochloride are projected to propel market growth. To cite an instance, in May 2023, Eyenovia, Inc. received approval from the U.S. FDA for its Mydcombi, a 1%/2.5% tropicamide and phenylephrine hydrochloride ocular spray used in mydriasis for diagnostic procedures and in cases with desired short-term pupil dilation.
The phenylephrine hydrochloride industry is segmented into application, mode, use, and region.
As per mode, the market share from the contract manufacturing segment is anticipated to record 7.9% CAGR from 2023-2032. Contract manufacturing offers pharmaceutical companies a strategic approach to streamline production and optimize costs. Additionally, outsourcing the manufacturing processes to specialized contract manufacturers ensures efficient production, quality compliance, and scalability. This mode also allows pharmaceutical firms to focus on R&D activities while leveraging the expertise of contract manufacturers for timely and cost-effective production of phenylephrine hydrochloride-based medications.
In terms of application, the phenylephrine hydrochloride industry from the allergic reaction segment generated substantial revenue in 2022 and is poised to depict 7% growth rate from 2023 to 2032. This can be attributed to increasing use in medications for relieving nasal congestion associated with allergic reactions. The rising prevalence of allergies, environmental factors, and the changing lifestyles is also surging the need for pharmaceuticals containing phenylephrine hydrochloride, thereby fueling the segment growth.
Regionally, the Asia Pacific phenylephrine hydrochloride market is anticipated to exhibit 8.1% CAGR from 2023-2032 driven by the expanding pharmaceutical and healthcare sectors. The rising prevalence of respiratory conditions and the incessant need for decongestant medications is leading to the increased demand for phenylephrine hydrochloride. Additionally, the rising population, urbanization, and the changing lifestyles across major APAC countries are fueling the preference for over-the-counter medications, further boosting the regional industry outlook.